Lascufloxacin

Lascufloxacin
Clinical data
Trade names	Lasvic
Other names	KRP-AM1977
Identifiers
	IUPAC name 7-[(3S,4S)-3-[(Cyclopropylamino)methyl]-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid;
CAS Number	848416-07-9;
PubChem CID	71528768;
IUPHAR/BPS	10823;
ChemSpider	34985131;
UNII	55MOB566V7;
KEGG	D10772;
CompTox Dashboard (EPA)	DTXSID001336967 ;
Chemical and physical data
Formula	C21H24F3N3O4
Molar mass	439.435 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C2C(=CC(=C1N3C[C@@H]([C@@H](C3)F)CNC4CC4)F)C(=O)C(=CN2CCF)C(=O)O;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Lascufloxacin (trade name Lasvic) is an fluoroquinolone antibiotic drug for the treatment of bacterial infections. It has been approved since 2019 in Japan^[1] to treat community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections.^[2]

It has activity against various Gram-positive bacteria including Streptococcus pneumoniae^[3] and Streptococcus anginosus.^[4]

References

^ "Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent Lasvic Tablets 75 mg" (PDF) (Press release). Kyorin Pharmaceutical Co. September 20, 2019. Retrieved July 3, 2021.
^ "Lascufloxacin - Kyorin Pharmaceutical". Adis Insight. Retrieved July 3, 2021.
^ Murata M, Kosai K, Yamauchi S, Sasaki D, Kaku N, Uno N, Morinaga Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K (April 2018). "In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions". Antimicrob Agents Chemother. 62 (4). doi:10.1128/AAC.01971-17. PMC 5913943. PMID 29439959.
^ Yamagishi Y, Matsukawa Y, Suematsu H, Mikamo H (December 2018). "In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group". Anaerobe. 54: 61–64. doi:10.1016/j.anaerobe.2018.08.002. PMID 30114441. S2CID 52015090.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] "Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent Lasvic Tablets 75 mg" (PDF) (Press release). Kyorin Pharmaceutical Co. September 20, 2019. Retrieved July 3, 2021.

[2] "Lascufloxacin - Kyorin Pharmaceutical". Adis Insight. Retrieved July 3, 2021.

[3] Murata M, Kosai K, Yamauchi S, Sasaki D, Kaku N, Uno N, Morinaga Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K (April 2018). "In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions". Antimicrob Agents Chemother. 62 (4). doi:10.1128/AAC.01971-17. PMC 5913943. PMID 29439959.

[4] Yamagishi Y, Matsukawa Y, Suematsu H, Mikamo H (December 2018). "In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group". Anaerobe. 54: 61–64. doi:10.1016/j.anaerobe.2018.08.002. PMID 30114441. S2CID 52015090.

[1]

[2]

[3]

[4]